| abstract |
The present invention relates to compounds of formula I and their pharmaceutically acceptable salts. In the formula (I), Y is a group of the formula (1), (2) or (3); each R 1 is independently hydrogen or alkyl; R1 and R2 are independently hydrogen, alkyl, -OH, - (CH2) n aryl, - (CH2) n- (substituted aryl) -, - (CH2) nO-aryl, - (CH2) nO- (substituted aryl) ) -, - (CH2) nS-aryl-, - (CH2) nS- (substituted aryl) -, - (CH2) nS-heteroaryl, - (CH2) nS- (substituted heteroaryl) -, - (CH2) n -NR'-aryl-, - (CH2) n-NR '- (substituted aryl) -, - (CH2) n-NR'-heteroaryl, - (CH2) n-NR' - (substituted heteroaryl) -, - (CH2) n-heteroaryl or - (CH2) n- (substituted heteroaryl); each n is independently 0-6; R3 is hydrogen or alkyl; R4 is alkyl or hydrogen, and X is hydrogen, substituted alkylsulfonylaminoalkyl, - (CH2) n-S- (CH2) n- (substituted aryl), or (10) or (11). The present invention further provides pharmaceutical compositions for the treatment of stroke, inflammatory diseases, including inflammatory diseases of the gut, and rheumatoid arthritis, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and multiple sclerosis prophylaxis, as well as the use of the above active ingredients. furthermore, for the preparation of pharmaceutical compositions for inhibiting interleukin-1b converting enzyme. HE |